Single infusions of MDCO-216 (ApoA1 Milano/POPC) were well tolerated in healthy volunteers and in patients with stable CAD
Presentation prepared and held by dr. David Kallend (Zürich, Switzerland) in Clinical Breakthroughs session: Modifying LDL cholesterol to prevent CV events, Tuesday, May 26, 2015 during ISA2015 (Amsterdam, The Netherlands).
To view slides, click on images
ISA_2015_slides_Kallend_et_al.pdf (0,9MB)
To view slides, click on images
ISA_2015_slides_Kallend_et_al.pdf (0,9MB)
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
Share this page with your colleagues and friends: